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Abstract: The majority of inactivating mutations of p53 reside in the central
 core DNA 
binding domain of the protein. In this computational study, we investigated the structural 
effects of a novel p53 mutation (G389E), identified in a patient with congenital adrenal 
hyperplasia,  which  is  located  within  the  extreme  C-terminal domain (CTD) of p53, an 
unstructured, flexible region (residues 367–393) of major importance for the regulation of 
the protein. Based on the three-dimensional structure of a carboxyl-terminal peptide of p53 
in complex with the S100B protein, which is involved in regulation of the tumor suppressor 
activity, a model of wild type (WT) and mutant extreme CTD was developed by molecular 
modeling and molecular dynamics simulation. It was found that the G389E amino acid 
replacement has negligible effects on free p53 in solution whereas it significantly affects 
the  interactions  of  p53  with  the  S100B  protein.  The
 results  suggest  that  the  observed 
mutation may interfere with p53 transcription activation and provide useful information for  
site-directed mutagenesis experiments.  
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1. Introduction  
Unstructured regions are a common motif of transcription factors [1]. One such example is the 
cancer suppressor protein p53, for which it has been outlined that unstructured and structured parts 
function synergistically [2]. p53 is a transcription factor that responds to oncogenic stress by inducing 
cell cycle arrest or apoptosis [3] and whose inactivation is mainly due to mutations that interfere with 
the DNA-binding activity of the protein [4,5]. The p53 protein consists of 393 residues and can be 
divided into three functional regions: (i) an N-terminal domain (1–93) containing a transcriptional 
activation  domain  and  a  proline-rich  domain;  (ii)  a  core  DNA-binding  domain  (102–292),  which 
contains most of the inactivating mutations found in human tumors; and (iii) a C-terminal domain 
(CTD) consisting of a tetramerization domain (320–356) and a regulatory domain (363–393). The 
extreme CTD, which binds to non-specific DNA sequences, is in fact of major importance for the 
regulation of the protein [6]. It seems to have a negative effect on specific DNA-binding activity of the 
core domain or by altering the conformation of p53 or by interfering by steric hindrance with the ability 
of the full-length protein to bind DNA [7,8]. Deletion of this regulatory region, binding of antibodies, 
phosphorylation and acetylation abolish the negative effect on DNA binding [9]. In particular, it has 
been  observed  that  phosphorylation  and/or  mutations  in  this  area  enhance  the  stability  of  the  
protein [10–12]. 
Mutations  of  the  tumor  suppressor  protein  p53  are  associated  with  more  than  50%  of  human 
cancers; however, almost 30% of p53 mutations occur rarely and this has raised questions about their 
significance [13]. It therefore appeared of particular interest that we could identify a novel mutation 
(G389E) within the carboxy-terminal regulatory region, in a patient suffering from congenital adrenal 
hyperplasia (CAH) [14]. 
Computational  methods  have  been  successfully  used  to  predict  the  effects  of  mutations  on  the 
structure and function of a protein before time consuming experiments are carried out [15,16]. In this 
study, investigations of structural consequences of this novel p53 G389E mutation are explored using 
molecular modeling and molecular dynamics (MD) simulations. In the absence of a three-dimensional 
structure  of  the  whole  extreme  C-terminus,  the NMR structure of a p53 peptide corresponding to 
Ser367–Glu388 residues, bound to S100B protein, was used as the starting structure for molecular 
modeling [17]. S100B, a member of the S100 family of EF-hand calcium-binding proteins, has been 
shown  to  contribute  to  cancer  progression  in  malignant  melanoma  by  interacting  with  p53  and 
inhibiting  its  function  as  a  tumor  suppressor  [18].  As  a  result  of  S100B  binding,  important  
post-translational  modifications  on  p53  are  blocked  and  p53  dependent  transcription  activation  is 
inhibited [19–21]. To provide an overall assessment of the effects of G389E mutation, MD simulations 
of wild type (WT) and mutant (G389E) peptides corresponding to the extreme CTD, free in solution 
and in complex with S100B, were then performed. Our results provide evidence to suggest that the 
novel  mutation  does  not  induce  relevant  structural  changes  of  p53  CTD  free  in  solution.  Instead, 
analysis of MD trajectories highlights the potential effects of G389E replacement on the interactions of 
p53 with S100B. Int. J. Mol. Sci. 2011, 12                       
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2. Results and Discussion  
2.1. Molecular Modeling  
Twenty structural models of WT and G389E p53 extreme CTD were built using MODELLER [22] 
and the NMR complex between a p53 peptide (residues 367–388) and S100B as starting structure (pdb 
1DT7) [17]. The 389–393 peptide sequence, which was not resolved in 1DT7 NMR structure, was 
modeled  ab  initio  [22].  Among  the  obtained  conformations  of  the  generated  complexes,  one  was 
selected on the basis of the lowest MODELLER objective function. The goodness of the selected 
folding was assessed by VERIFY-3D [23], which evaluates the compatibility of a given residue in a 
certain  three-dimensional  environment.  A  score  below  zero  for  a
  given  residue  means  that  the 
conformation adopted by that residue
 in the model is not compatible with its surrounding environment. 
As shown in Figure 1, the 3D-1D
 dimensional scores of the models generated by VERIFY-3D are 
always positive. The validity of the modeled structural motifs is highlighted by the absence of negative 
score regions in the plots; it is worth noticing that the VERIFY-3D plot of the NMR 1DT7 starting 
structure displays a negative score region (Figure 1). 
Figure 1. VERIFY-3D plots of molecular complexes of WT (black continuous line) and 
G389E (grey line) p53 peptide bound to S100B compared to the starting NMR structure 
1DT7  (black dashed line). Although a negative score region is present in the template 
structure, the modeled structural motifs are characterized by the absence of negative score 
regions in the plots. Residues are numbered consecutively by VERIFY-3D from the amino 
terminus of S100B. 
 
 
The geometry of the selected models was also checked with PROCHECK [24] showing that no 
residue has a disallowed geometry. Int. J. Mol. Sci. 2011, 12                       
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2.2. Molecular Dynamics Simulations of WT and G389E Unbound Peptides 
The  effects  of  G389E  replacement  on  the  unbound  peptide  conformations  were  evaluated  by 
molecular (MD) simulations. The p53 extreme C-terminus exists as a random coil in its native form 
and  becomes  helical  (residues  Ser376-Thr387)  when  bound  to  S100B,  as  demonstrated  by  NMR 
spectroscopy [17]. Therefore, MD simulations at 300 K also enabled us to compare experimental data 
with the predictions drawn from computer simulated models determining whether the helix unfolds on 
a reasonable time scale. The simulations were started from the minimized structures of wild type and 
mutant  peptides  taken  from  the  corresponding  S100B  model  complexes  and  continued  for  40  ns. 
Examination  of  backbone  atom  root-mean-square  deviations  (RMSD)  (Figure  2)  relative  to  the  
energy-minimized conformations, suggests that both peptides unfold (RMSD higher than 0.6 nm). 
Figure  2.  Backbone  atom  root-mean-square  deviations  (RMSD)  for  WT  (black)  and 
G389E (red) p53 extreme C-terminus domain free in solution from their corresponding 
starting structure. 
 
 
Snapshots of the unfolding pathways are reported in Figure 3. The helix of the WT peptide rapidly 
unfolds by eight residues in the first 0.89 ns of simulation with an increase of the RMSD value to 
0.41 nm (Figure 3A). The shorter helix spans residues 381–383 and it is stable to 25 ns, followed by 
further and complete unfolding at 30 ns (Figure 3A). In the simulation of the G389E peptide, the 
unfolding is more rapid and leads to higher RMSD values (Figure 2). A common feature with the WT 
simulation is the rapid loss of most of the helix structure in the first nanosecond (Figure 3B), but 
thereafter the RMSD increases rapidly reaching 0.6–0.65 nm in 3.0 ns when a complete loss of the 
helical structure was detected (Figure 3B). The snapshots of the mutant peptide clearly show a decrease 
in the time spent in the helical conformation compared to the WT peptide (Figure 3B). In agreement 
with the NMR studies, therefore, the MD simulations confirm that in the absence of S100B the p53 
extreme C-terminus exists in solution in a disordered structure. Int. J. Mol. Sci. 2011, 12                       
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Figure  3.  Representative  snapshots  taken  from  the  40  ns  simulations  of  WT  (A)  and 
G389E (B) p53 extreme C-terminus domain free in solution. 
 
In addition, MD results show that replacement of Gly389 with Glu, occurring in a random coil 
region,  causes  localized  structural  changes  with  no  significant  effects  on  the  phosphorylation  and 
acetylation sites near the carboxyl terminus. An illustration of the snapshots of WT and G389E p53 
peptide simulations at 40 ns is reported in Figure 4.  
Figure 4. Cartoon representation of the snapshots of WT (A) and G389E (B) p53 peptide 
simulations at 40 ns showing the distances of residue 389 from the main phosphorylation 
and acetylation sites at the C-terminus of p53. 
 
 
The figure displays the distances of Glu389 residue from Lys382 and Ser392, and highlights the 
negligible  effect  exerted  by  position  389  on  the  main  acetylation  and  phosphorylation sites at the  
C-terminus of p53 [6]. Analysis of MD trajectories indicates that during the entire 40 ns of simulation, 
Glu389 is solvent exposed and does not interact with other residues of the extreme CTD. Int. J. Mol. Sci. 2011, 12                       
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2.3. Molecular Dynamics Simulations of WT and G389E Peptides Bound to S100B 
The available NMR structure of p53 in complex with S100B gave us the opportunity to assess the 
role of this mutation also in the context of the intermolecular interactions which down-regulate the 
tumor suppressor function. The interaction of p53 with S100B is of particular interest because while 
most proteins that bind or modify the C-terminal of p53 activate the tumor suppressor, the opposite 
effect  is  observed  for  S100B  which  causes  inhibition  of  phosphorylation  and  of  p53  dependent 
transcription activation [20,21]. It was found that phosphorylation (at positions Ser376, Thr377) and 
acetylation (at position Lys382) reduce the affinity of the S100B-p53 interaction [25] and are therefore 
important for protecting p53 from S100B-dependent downregulation.  
A 40 ns classical MD simulation including explicit water of the two complexes was carried out.  
The  root  mean  square  deviation  (RMSD)  of  the  backbone  atoms  relative  to  the  corresponding 
starting structures was calculated and the results are reported in Figure 5.  
Figure  5.  RMSD  plots  of  S100B  complexes  throughout  the  MD  simulations.  
(A) Backbone atom RMSD with WT (black) and G389E (red) peptide of p53 included;  
(B) Backbone atom RMSD with WT (black) and G389E (red) peptide of p53 excluded. 
 
 
As shown in figure, both complexes are rather flexible (Figure 5A). A closer inspection of the 
RMSD indicates that its variation is mainly due to the C-terminal p53 peptide, this effect being more 
pronounced in the G389E complex, while S100B is rather stable in both simulations (Figure 5B).  
The deviations described above indicate how far the protein has moved from the starting structure. 
The  Cα  root-mean-square  fluctuations  (RMSF)  with  respect  to  the  average  MD  conformation  are 
extremely appropriate to describe flexibility differences among residues (Figure 6).  Int. J. Mol. Sci. 2011, 12                       
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The RMSF profile over the whole simulation period of 40 ns shows that comparable fluctuations 
were found for S100B in both WT and G389E runs (Figure 6A). Large fluctuations from the averaged 
MD  conformations  were  found  at  the  C-  and  N-termini  while  the  four  S100B  helix  
structures (2–19, 29–40, 49–61 and 70–88) were consistently stable, with RMSF around 0.1–0.15 nm. 
A detailed analysis reveals a higher flexibility in few turns of helix 3 and helix 4 of the WT complex 
compared with the mutant one. A larger fluctuation of helix 1 (residues 2–19) was observed in the 
G389E  run.  Taken  together,  the  substitution  of  Gly389  in  p53  does  not  destabilize  the  overall 
organization of S100B.  
Figure 6. Residue-based Cα RMSF relative to the average structure for S100B (A) and  
p53 peptide (B) in WT (black) and G389E (red) complexes.  
 
 
Consistent with the RMSD analysis, the G389E peptide also displayed a larger RMSF as compared 
to the WT (Figure 6B). A remarkable enhancement in mobility of the helix segment of the peptide is 
observed, which can be thought of as an adaptive motion. 
Secondary structure analysis was carried out to explore whether the sizable RMSD and RMSF of 
the p53 peptide result from a different orientation in the MD simulation compared to the starting 
structure or from secondary structure changes. 
According to NMR studies [17], much of the C-terminal p53 peptide (Ser376–Thr387) adopts a 
helical conformation when bound to the S100B protein. The binding surface in the p53 peptide-S100B Int. J. Mol. Sci. 2011, 12                       
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complex is defined by few residues from loop 2 (extending from residue 41 to 48), helix 3 (extending 
from residue 49 to 61) and helix 4 (extending from residues 70 to 87) of S100B and by residues  
375–388 of p53. The time evolution of the secondary structure elements is depicted in Figure 7.  
In the WT, run all secondary structure elements of S100B can be considered as stable. The peptide 
helical conformation (residues 376 to 387) is lost during the simulation and partially refolds into a sort 
of helix, which is assigned as an α-helix and transiently as a 310-helix (Figure 7A). In the case of the 
G389E run, we observe that S100B helix 4 is less persistent, with a loss of α-helix at its terminus, 
whereas the mutant peptide increases its α-helix content (Figure 7B).  
Figure 7. Secondary structure of S100B complexes as a function of time. Results for WT 
peptide- and G389E peptide-S100B complexes are reported in (A) and (B), respectively. 
 
 
In Figure 8 snapshots of the 40 ns MD simulations for the two complexes are presented. 
Focusing  on  the  WT  p53  peptide,  during  the  first  0.1  ns,  the  helical  structure  starts  to  unfold  
(Figure  8A).  The  instability  of  the  p53  C-terminal  peptide  in  complex  with  S100B  during  MD 
simulation has been already reported by Whitlow et al. [26]. It is worthwhile noting that they used two 
different force fields, namely CHARMM27 and AMBER, and their findings are in excellent agreement Int. J. Mol. Sci. 2011, 12                       
 
 
136
with ours, i.e., the WT complex is not stable in the MD with a backbone RMSD comprised between  
5 Å and 6 Å in the last 5 ns of simulation, values comparable with those found in Figure 5A. They also 
observed,  in  agreement  with  our  study,  that  the  helical  structure  of  the  p53 C-terminal peptide is 
gradually lost during simulation. A possible explanation for this result may be that the C-terminal 
peptide is only a small fraction of p53 and therefore characterized by structural instability [26]. At the 
end of the simulation, a large conformational change of the WT p53 peptide is observed, coinciding 
with a severe loss of α-helical structure (Figures 8A and 7A). This conformational change starts after 
28 ns of the MD simulation. Snapshots from simulation show that the WT peptide is in a closed 
conformation. Favorable electrostatic interactions between the charged residues within the p53 extreme 
CTD enable bending of peptide in correspondence with the mutation site. The residues responsible for 
these electrostatic interactions were the negatively charged Asp391 and Asp393, which alternatively 
interacted with positively charged Lys370, Lys372 and Lys373. Direct salt bridges have been assumed 
to be around 4.3 Å, whereas indirect or water-mediated salt bridges have been assumed to have a 
distance between 4.3 and 7.0 Å [27]. The direct salt bridge between Asp391 and Lys373 was very 
strong (Figure 8C) persisting through most of the MD simulation. A hydrogen bond between the O 
backbone atom of Glu388 and the OG1 atom of Thr377 is indicated by a distance of 2.6 Å in the 
average structure, contributing to the closed peptide conformation. This interaction is stable during 
most of the MD simulation based on a critical hydrogen bond distance of <3.5 Å. 
Replacement of Gly by Glu, which is expected to restrict the conformational freedom of the peptide 
backbone  at  this  point,  imparts  a  more  rigid  structure  to  the  corresponding  region  of  the  p53  
C-terminus and prevents the p53 extreme CTD from its bending (Figure 8B). Moreover, introduction 
of  the  negatively  charged  Glu389  residue  moves  Glu388  far  away  from  potential  interacting  
C-terminal residues. This results in a different orientation of the peptide and in a slight increase of its 
helical content as the simulation progresses (Figures 8B and 7B). Both effects may therefore account 
for the increased RMSD observed for the mutant p53 peptide (see Figure 5A). First, only few turns of 
the peptide helix remain packed against helix 4 of S100B, and thereafter, the whole peptide helix is 
flanking helix 4 (Figure 8B). In the mutant complex, the salt bridges observed within the WT extreme 
CTD were never formed, while Lys382 and Lys370 stably anchor the mutant peptide to helix 4 of 
S100B. In fact, the distance between Lys382 NZ atom and Thr82 OG1 is below the hydrogen bond 
distance threshold (Figure 8D) as well as the distance between Lys370 NZ atom and Glu89 OE1 atom 
becomes stable during the MD run forming a direct salt bridge (Figure 8D). 
In both WT and mutant systems the hydrophobic Leu383 of the p53 C-terminal interacts with a 
hydrophobic patch on S100B involving Met79, Leu44 and Val56 of S100B (Figure 8C, D). Upon 
G389E mutation, and as a consequence of peptide moving, the hydrophobic residue Leu369 provides 
favorable contributions to hydrophobic force establishing a close contact with S100B Phe87.  
On  the  basis  of  MD  results,  we  therefore  predict  that  the  stability  of  the  p53  peptide-S100B 
complex, upon G389E substitution, is increased. As a consequence, the affinity of the S100B-p53 
interaction might be altered and the biological function of p53 as a tumor suppressor further disabled.  
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Figure 8. Snapshots from the simulated complexes during the MD runs. Plots of WT (A) 
and G389E (B) complex intermediates generated by the MD simulation at the indicated 
times. S100B and p53 peptides are represented by green and red cartoons, respectively. The 
loss of secondary structure in the WT peptide (A) and the movement of the helix in the 
G389E peptide (B), as a function of time, are noteworthy. Average structures over the last 5 
ns  of  simulation  of  the WT and G389E complexes are reported in panel (C) and (D), 
respectively. 
 
3. Experimental Section  
3.1. Molecular Modeling  
The sequence of the extreme C-terminus (residues 367-393) of p53 is  
SHLKSKKGQSTSRHKKLMFKTEGPDSD 
with the amino acid 389 in bold. 
The  three-dimensional  structure  of  the  carboxyl-terminal  peptide  of  p53  (residues
 367–388)  in 
complex with S100B protein was taken from the
 Protein Data Bank (code 1DT7 [17]) and used as 
initial structure for molecular modeling. The sequence 389–393, which was not resolved in 1DT7 
structure, was built with an ab initio modeling routine of MODELLER as implemented in Discovery 
Studio (Accelrys Inc.) [2]. Twenty alternative conformations of the WT and G389E extreme CTD in 
complex with S100B were generated. The geometrical consistency of the models was evaluated based Int. J. Mol. Sci. 2011, 12                       
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on the probability density function (PDF) violations provided by MODELLER. After visual inspection 
using the computer graphics program Discovery Studio 2.1 (Accelrys Inc.), a representative model 
from  each  set,  used  for  all  subsequent
 studies,  was  chosen,  which  corresponded
 to  low  restraints 
violations and to favorable
 geometrical and stereochemical properties as checked
 with VERIFY-3D and 
PROCHECK [24,28].  
3.2. Molecular Dynamics Simulations  
Forty  nanosecond  MD  simulations  of  WT  and  G389E  extreme  CTD,  free  in  solution  and  in 
complex  with  S100B,  were  performed  using  GROMACS  software  version  4.0.5  with  the  
OPLS-(AA)/L all-atom force field [29]. For the simulations of unbound peptides, the starting structures 
were extracted from the complexes with S100B. Each peptide and complex was immersed in a cubic 
box  extending  to  at  least  0.9  nm  from  the  protein  surface  and  solvated  with  explicit  SPC  water 
molecules. Chloride and sodium ions were added to neutralize the systems (peptides and complexes, 
respectively) which were then simulated with periodic boundary conditions. The final peptide systems 
consisted  of  435  and  443  protein  atoms  (wild  type  and  mutant,  respectively)  surrounded  by  
∼4,000  water  molecules,  whereas  the  final  complex  systems  consisted  of  1,895  and  1,903 protein 
atoms (wild type and mutant, respectively), surrounded by ∼13,000 water molecules. Before running 
the simulation, each system was energy minimized for 1,000 iterations of steepest descents and then 
equilibrated  for  20  ps,  during  which  the  protein  atoms  were  restrained.  All  restraints  were  then 
removed  from  the  complexes  and  the  temperature  was  gradually  increased  in  10  distinct  steps  of  
5 ps simulations each.  
Berendsen coupling was employed to maintain a constant temperature of 300 K with a coupling 
constant τ of 0.1 ps. van der Waals interactions were modeled using 6–12 Lennard-Jones potentials 
with a 1.4 nm cutoff. Long-range electrostatic interactions were calculated using particle mesh Ewald 
method [30], with a cutoff for the real space term of 1.2 nm. Covalent bonds were constrained using 
the Lincs algorithm [31]. The time step employed was 2 fs and the coordinates were saved every 5 ps 
for analysis of MD trajectories. Secondary structure was calculated using the DSSP algorithm [32] 
within GROMACS and all other analyses were performed using GROMACS utilities.  
4. Conclusions  
In this study, the main goal of MD simulation was essentially to make predictions of the effects of a 
novel p53 mutation (G389E), opening possibilities for exploring properties of the molecular system 
under  investigation  that  are  less  accessible  by  conventional  experimental  methods.  Our  main 
conclusions are as follows. First, our studies indicate that the p53 G389E mutation has negligible effect 
on the protein when it is free in solution. Second, (in agreement with previous simulations of the p53 
extreme C-terminus in complex with S100B [26]) the helical WT peptide gradually loses its secondary 
structure during simulation. Third, and perhaps most importantly, it was found that in the presence of 
this novel mutation the binding surface between the p53 C-terminus and S100B is significantly altered, 
thus further preventing p53 from functioning. The results reported herein strengthen the role of the 
intermolecular  interactions  in  p53  activity  and  provide  useful  information  for  the  design  of  
appropriate mutants.  Int. J. Mol. Sci. 2011, 12                       
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